LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Suletud

SektorTervishoid

16.81 -0.88

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.76

Max

16.91

Põhinäitajad
By Trading Economics
Sissetulek	614M 331M
Müük	288M 731M
P/E Sektori keskmine	47.771 49.701
Aktsiakasum	3.16
Kasumimarginaal	45.287
Töötajad	835
EBITDA	624M 372M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+31.25% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-562M 1.8B
Eelmine avamishind	17.69
Eelmine sulgemishind	16.81

Uudiste sentiment

By Acuity

50%

159 / 345 Pingereas Healthcare

Sarepta Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. juuli 2025, 15:04 UTC

Suurimad hinnamuutused turgudel

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21. juuli 2025, 11:31 UTC

Suurimad hinnamuutused turgudel

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26. jaan 2026, 09:55 UTC

Kuumad aktsiad

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4. nov 2025, 14:39 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4. nov 2025, 12:45 UTC

Tulu

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11. aug 2025, 11:48 UTC

Tulu

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11. aug 2025, 11:11 UTC

Tulu

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29. juuli 2025, 21:11 UTC

Tulu

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29. juuli 2025, 12:14 UTC

Tulu

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29. juuli 2025, 11:46 UTC

Tulu

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21. juuli 2025, 12:53 UTC

Tulu

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21. juuli 2025, 11:17 UTC

Tulu

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21. juuli 2025, 10:25 UTC

Tulu

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21. juuli 2025, 09:50 UTC

Tulu

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21. juuli 2025, 09:12 UTC

Tulu

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17. juuli 2025, 16:44 UTC

Tulu

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17. juuli 2025, 13:48 UTC

Tulu

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17. juuli 2025, 10:57 UTC

Tulu

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17. juuli 2025, 09:08 UTC

Kuumad aktsiad

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17. juuni 2025, 09:10 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17. juuni 2025, 08:59 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16. juuni 2025, 08:55 UTC

Kuumad aktsiad

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Võrdlus sarnastega

Hinnamuutus

Sarepta Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

31.25% tõus

12 kuu keskmine prognoos

Keskmine 22.05 USD 31.25%

Kõrge 38 USD

Madal 5 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Sarepta Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Sarepta Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

159 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.